Shares of Retrophin Inc (NASDAQ:RTRX) have been assigned a consensus rating of “Buy” from the thirteen brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $27.75.
Several research firms have recently commented on RTRX. ValuEngine raised Retrophin from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Nomura reduced their price objective on Retrophin from $57.00 to $33.00 and set a “buy” rating for the company in a research report on Friday, August 23rd. Zacks Investment Research upgraded Retrophin from a “hold” rating to a “strong-buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, November 6th. BidaskClub upgraded Retrophin from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Leerink Swann set a $35.00 target price on Retrophin and gave the stock a “buy” rating in a research report on Thursday, August 22nd.
In other news, Director Steve Aselage sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $13.91, for a total transaction of $69,550.00. Following the completion of the transaction, the director now owns 250,966 shares in the company, valued at approximately $3,490,937.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.32% of the stock is currently owned by corporate insiders.
NASDAQ:RTRX opened at $13.13 on Wednesday. The company has a quick ratio of 4.94, a current ratio of 5.00 and a debt-to-equity ratio of 0.82. The business’s 50 day moving average is $12.50 and its two-hundred day moving average is $15.82. Retrophin has a 52 week low of $10.87 and a 52 week high of $25.55. The company has a market cap of $566.08 million, a PE ratio of -5.17 and a beta of 0.83.
Retrophin (NASDAQ:RTRX) last released its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.55. Retrophin had a negative net margin of 71.70% and a negative return on equity of 43.88%. The firm had revenue of $44.37 million during the quarter, compared to analyst estimates of $45.31 million. During the same quarter in the previous year, the firm earned ($0.68) earnings per share. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. As a group, sell-side analysts expect that Retrophin will post -3.45 EPS for the current fiscal year.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Story: Why are trading ranges significant?
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.